Two doses of recombinant zoster vaccine provides strong protection over 4 years even in immunocompromised patients
Recent research evaluating the long-term effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster, commonly known as shingles, has shed light on its protective benefits over several years. The study, conducted by Ousseny Zerbo, PhD, and colleagues at Kaiser Permanente Northern California Division of Research, highlights the vaccine's sustained efficacy, especially in individuals receiving two doses.
Vaccine Effectiveness: The study involved nearly 2 million participants aged 50 years and older, contributing over 7.6 million person-years of follow-up. After adjustment for various factors, researchers found the overall vaccine effectiveness was 64% for one dose and 76% for two doses of RZV.
Long-Term Protection: Individuals receiving two doses exhibited notable effectiveness, with a 73% protection rate against shingles after 3 to 4 years. In contrast, those with partial vaccination showed a lower efficacy of 52% after 4 years.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.